2015.9 – 2018.7 复旦大学药学院 博士
2012.9 – 2015.7 郑州大学药学院 硕士
2008.9 – 2012.7 郑州大学药学院 本科
2020.9 – 至今 复旦大学生物药物学系 青年研究员
2018.7 – 2020.8 宾夕法尼亚大学肿瘤生物学 博士后
1、 衢州复旦研究院，原创性新药的转化与开发项目，2025-2028，主持
2、 上海市科学技术委员会，“科技创新行动计划” 细胞与基因治疗专项，2024-2027，项目骨干
3、 国家重点研发计划“主动健康和人口老龄化科技应对”青年科学家项目，2024-2026，项目骨干
4、 国家重点研发计划“中医药现代化”重点专项，2023-2027，项目骨干
5、 国家自然科学基金委，青年科学基金项目，2023-2025，主持
6、 上海市科学技术委员会，科技创新行动计划，2021-2024，主持
7、 复旦大学，复旦大学引进人才科研基金，2021-2025，主持
2024 ESMO Merit Travel Grant, European Society for Medical Oncology
2023 JSMO Annual Meeting, Japan. Oral Presentation & Travel Award
2021 上海市青年科技英才“扬帆计划”入选者
2021 上海海外高层次引进人才
2017 ESMO Immuno Oncology Congress 2017, Switzerland. Poster Discussion & Travel Award
2017 宝钢教育奖学金 特等奖
2016 ESMO Asia 2016 Congress, Singapore. Poster Presentation & Travel Award
1. 新型免疫治疗药物研发
2. 微环境与肿瘤免疫治疗机制研究
1. Nan Y, Zhu M, Wang Q, Du X, Xu C, Huang Y, Liu Y, Zhou S, Qiu Y, Chu X*, Ju D*, Wan Y*, Zhang X*. Nanobody-Engineered Bispecific IL-18 Mimetics Drive Antitumor Immunity by Engaging CD8+ T Cells and Evading IL-18BP in Preclinical Models. Molecular Therapy. 2025 Jul 16:S1525-0016(25)00540-4.
2. You L, Wang Q, Zhang T, Xiao H, Lv M, Lv H, Deng L, Zhang X*, Zhang Y*. USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells. Oncogene. 2025;44:2413-2426.
3. Zhang X#, Feng Z#, Pranatharthi Haran A#, Hua X*. Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs. Oncoimmunology. 2025;14:2458843.
4. Wang S*, Wang SQ, Chen XB, Xu Q, Deng H, Teng QX, Chen ZS, Zhang X*, Chen FE*. Cell-Based Screen Identifies a Highly Potent and Orally Available ABCB1 Modulator for Treatment of Multidrug Resistance. Journal of Medicinal Chemistry. 2024;67:18764-18780.
5. Xu C, Huang X, Hu Q, Xue W, Zhou K, Li X, Nan Y, Ju D*, Wang Z*, Zhang X*. Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer. Biomedicine & Pharmacotherapy. 2024;180:117550.
6. Xue W, Xu C, Zhang K, Cui L, Huang X, Nan Y, Ju D*, Chang X*, Zhang X*. Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer. Cell Death Discovery. 2024;10:393.（ESI热点论文）
7. Nan Y, Bai Y, Hu X, Zhou K, Wu T, Zhu A, Li M, Dou Z, Cao Z, Zhang X, Xu S, Zhang Y, Lin J, Zeng X, Fan J, Zhang X*, Wang X*, Ju D*. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. Journal for ImmunoTherapy of Cancer. 2024;12:e009236.
8. Wang Y, Nan Y, Ma C, Lu X, Wang Q, Huang X, Xue W, Fan J, Ju D*, Ye D*, Zhang X*. A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE. Cell Death Disease. 2024;15:293.
9. Zhang K, Xu Y, Chang X, Xu C, Xue W, Ding D, Nie M, Cai H, Xu J, Zhan L, Han J, Cai T, Ju D, Feng L*, Zhang X*, Yin K*. Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer. Cancer Immunology Immunotherapy. 2024;73:75.
10. Xu C, Zhu M, Wang Q, Cui J, Huang Y, Huang X, Huang J, Gai J, Li G, Qiao P, Zeng X, Ju D*, Wan Y*, Zhang X*. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. Journal of Nanobiotechnology. 2023;21:410.（ESI高被引论文）
